Menu
Search
|

Menu

Close
X

Savara Inc SVRA.OQ (NASDAQ Stock Exchange Global Select Market)

7.86 USD
-0.18 (-2.24%)
As of Mar 22
chart
Previous Close 8.04
Open 8.00
Volume 62,474
3m Avg Volume 51,892
Today’s High 8.06
Today’s Low 7.68
52 Week High 14.06
52 Week Low 6.22
Shares Outstanding (mil) 24.20
Market Capitalization (mil) 229.69
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.71 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-1.905
FY17
-3.157
FY16
-6.540
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.54
Price to Sales (TTM)
vs sector
1,794.46
8.39
Price to Book (MRQ)
vs sector
2.88
5.27
Price to Cash Flow (TTM)
vs sector
--
24.12
Total Debt to Equity (MRQ)
vs sector
19.55
16.02
LT Debt to Equity (MRQ)
vs sector
18.65
11.35
Return on Investment (TTM)
vs sector
-43.82
13.82
Return on Equity (TTM)
vs sector
-65.80
15.24

EXECUTIVE LEADERSHIP

Robert Neville
Chairman of the Board, Chief Executive Officer, Since 2017
Salary: $210,938.00
Bonus: $276,750.00
David Lowrance
Chief Financial Officer, Since 2017
Salary: $204,271.00
Bonus: $88,100.00
Nevan Elam
Independent Director, Since 2017
Salary: --
Bonus: --
Richard Hawkins
Independent Director, Since 2017
Salary: --
Bonus: --
Joseph McCracken
Independent Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

900 S Capital of Texas Hwy Ste 1
WEST LAKE HILLS   TX   78746-5436

Phone: +1512.6141848

Savara Inc., formerly Mast Therapeutics, Inc., is an orphan lung disease company. The Company is engaged in the development and commercialization of novel therapeutics to address unmet medical needs. Its product pipeline include Molgradex, AeroVanc and Aironite. Molgradex is an inhaled formulation of recombinant human GM-CSF. It is developing Molgradex for the treatment of pulmonary alveolar proteinosis (PAP) and nontuberculous mycobacterial (NTM) lung infection. AeroVanc is a vancomycin hydrochloride inhalation powder. It is developing AeroVanc as an antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) lung infection in individuals living with cystic fibrosis (CF). Aironite is a sodium nitrite inhalation solution. Aironite is an investigational product. The Company is developing Molgradex in a pivotal Phase-III clinical trial for the treatment of PAP and in a Phase II a study for NTM lung infection. AeroVanc is in a Phase-III clinical trial.

SPONSORED STORIES